Your Source for Venture Capital and Private Equity Financings

eGenesis Raises $125M Series C Round

CAMBRIDGE, MA, eGenesis today announced the successful completion of a $125 million Series C financing.
eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful completion of a $125 million Series C financing. Funding will be used to bring the company's lead programs in kidney and islet cell transplant into human proof-of-concept studies. In addition, the funds will be used for continued development of the company's proprietary gene-editing platform and scaling of GMP production.

The financing from leading healthcare investors included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners. Existing investors including Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners participated.

eGenesis's goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need. The company harnesses cutting-edge gene editing technologies to address the key issues that have impeded xenotransplantation to date. eGenesis's development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors